Xenogen Corp. has launched its new IVIS 3D Imaging System, the first commercial three-dimensional biophotonic imaging system during the Fourth Annual Meeting of the Society for Molecular Imaging (SMI) in Cologne, Germany.
Leveraging Xenogen's expertise and intellectual property in biophotonic imaging, the company's IVIS 3D Imaging System is designed to help expedite drug discovery and development, and significantly reduce the cost and time to market for new therapies. The new unit is designed to provide even higher quality, more predictive data earlier in the drug discovery and development process.
Evaluation units of the IVIS 3D systems have been installed at several medical institutions, including the Children's Hospital Los Angeles and the Hospital for Sick Children in Toronto.
"Xenogen's new three-dimensional system enables us to see what's happening to cells inside a mouse, from multiple views and in real time," said Mark Henkelman, professor, Departments of Medical Biophysics and Medical Imaging, Canada Research Chair in Imaging, and director, Mouse Imaging Centre, Hospital for Sick Children. "It is an extremely sensitive camera, and it's now the only way to get data on patterns of emitted light in animals, data that we didn't have before. This technology will help us understand gene expression in mice and thus, better predict gene expression in humans."
Xenogen's non-invasive imaging systems enables scientists to better visualize, track and understand biological processes in living animals, in real time. The technology incorporates luciferase -- the enzyme that makes fireflies and some bacteria glow -- into living animals. Illuminating biological processes allows real-time visual exploration and analysis of gene expression, cellular pathways, drug/target interactions and the mechanism of action of drugs.